ANDOVER, Mass.--(BUSINESS WIRE)--InnoCentive announced today that Prize4Life, Inc., a non-profit organization founded to accelerate Lou Gehrig’s disease research, has offered a $1 million incentive to help advance the treatment for Amyotrophic Lateral Sclerosis. “This important challenge, identifying an ALS ‘biomarker,’ is an effort to identify a specific measurement for the disease that can aid in detection and response to therapy,” said Jill A. Panetta, Ph.D., InnoCentive’s Chief Scientific Officer.
